2. Role of the androgen receptor in triple-negative breast cancer
|
|
- Buddy French
- 6 years ago
- Views:
Transcription
1 Research Signpost 37/661 (2), Fort P.O. Trivandrum Kerala, India The Androgen-Excess Theory of Breast Cancer, 2012: ISBN: Editors: Giorgio Secreto and Barnett Zumoff 2. Role of the androgen receptor in triple-negative breast cancer Yoshinari Ogawa and Katsumi Ikeda Department of Breast-Surgical Oncology, Osaka City General Hospital, Miyakojima-hondori, Miyakojima-ku, Osaka, , Japan Abstract. Triple-negative breast cancer (TNBC) accounts for 15% to 25% of breast-cancer diagnoses. TNBC expresses neither estrogen nor progesterone receptors, nor does it overexpress human epidermal growth factor type-2 receptor. It is an aggressive form of cancer and has not been a specific target of therapies for breast cancer. While it is initially sensitive to chemotherapy, TNBC has a high rate of relapse and poor prognosis after such chemotherapy. More effective therapeutic options for this subset of breast cancer are needed. Androgen receptor (AR) is expressed in one-third of TNBCs, and recent studies have clarified its action in breast cancer. AR-targeted therapy is one of the envisioned new therapies for TNBC; the therapeutic approach can involve the inhibition of androgen synthesis, use of non-androgenic AR-binding hormones, inhibition of co-regulators, activation of membrane AR, and reassessment of medroxyprogesterone acetate. These approaches are being evaluated in studies at the preclinical and phase II levels. Targeted therapies that improve outcome in patients with TNBC are expected to be developed in the near future. Correspondence/Reprint request: Dr. Yoshinari Ogawa, Department of Breast-Surgical Oncology, Osaka City General Hospital, , Miyakojima-hondori, Miyakojima-ku, Osaka, , Japan m @med.osaka-cu.ac.jp
2 28 Yoshinari Ogawa & Katsumi Ikeda Introduction Breast cancer comprises a heterogeneous group of tumors that are diverse in behavior, outcome, and response to therapy. Recently, the clinical management of breast cancer has come to rely on biomarkers [1-3]. DNA microarray profiling of breast cancer has identified 5 distinct subtypes luminal A, luminal B, HER2-positive, basal-like, and normal-like breast cancer [4,5]. Considering these distinct subtypes is necessary for the management of breast cancer, in order to identify a proper therapeutic approach for the improvement of patient outcomes [1]. These genetic subtypes have overlapping immunohistochemical features [6-8]. Basal-like breast cancer (BLBC) likely represents a subset of triple-negative breast cancer (TNBC) that is estrogen-receptor (ER)-negative, progesteronereceptor (PR)-negative, and human epidermal-growth-factor-type-2 (HER2)- negative. ER, PR, and HER2 are the most valuable biomarkers in predicting the response to targeted therapy [2,3]. TNBC, which represents 15% to 25% of all breast cancers [9-12], has a more aggressive clinical course and does not benefit from conventional endocrine- and HER2-targeted therapy. Although patients with TNBC show a better initial response to chemotherapy, they do not have better overall survival; the short duration of the effects of cytotoxic agents in TNBC is associated with a higher likelihood of relapse and poorer prognosis in these patients [13-15]. While HER2-positive patients have a poor prognosis, similar to that of TNBC [16], the introduction of trastuzumab has significantly improved their prognosis [17]. Standardized targeting therapy and optimal standardized care have been lacking in the management of TNBC, but several pathways of interest are being studied. One such area of investigation is the role of the androgen receptor (AR) [11,18], which is expressed in one-third of TNBC patients. If AR is confirmed as biologically relevant in TNBC, it is possible that hormonal manipulations targeting it could be useful in the treatment of these tumors. This section reviews the expression of AR in TNBC and future plans for the development of AR-targeted therapies. AR expression in TNBC AR is expressed in 70% to 90% of primary breast cancers, an incidence comparable to or higher than that of either ER or PR [19,20]. Compared with other subtypes, TNBC has 25% to 45% lower AR levels [12,21-24]. AR expression is associated with good prognosis in ER-negative cancer [20,25] as well as in TNBC [21,23]. The relationship between AR expression and prognosis in ER-positive breast cancer is controversial: some studies have
3 AR in TNBC 29 shown that AR expression is related to good prognosis [26], others have reported no relationship between AR expression and prognosis [27]. In addition to prognostic prediction, it has been hoped that AR could predict the response to hormonal therapy in patients with AR- and ER/PR-positive breast cancer, or in patients with AR-positive and PIK3C-mutant TNBC [21]. Despite the prevalence of AR expression in both normal breast tissue and breast cancer, the clinical significance and functional role of AR and androgens in breast cancer are not well characterized [28,29]. Some epidemiologic studies report that the therapeutic use of testosterone in females is not associated with an increased risk of breast cancer [30]. Others show increased risk of breast cancer in postmenopausal women treated with estrogen and testosterone during 24 years follow-up [31]. Still others have recently reported that high plasma androgen levels are associated with an increased risk of breast cancer in postmenopausal women [32,33] and poor prognosis [34]. Early preclinical studies demonstrated that androgens exerted predominantly anti-proliferative effects on breast-cancer cells [35,36], but contradictory findings have been reported more recently [37-39]: androgens were found to induce proliferative changes in breast-cancer cell lines and to promote tumorigenesis in animal models by AR-mediated pathways [40,41]. These differences in the reports about AR and androgens in breast cancer may represent differences in experimental conditions. AR and ER are co-expressed in normal breast epithelial cells and in 80 90% of breast cancers. When AR is activated by 5α-dihydrotestosterone (5α-DHT), ER activity is inhibited in a dose-dependent fashion [26]. Co-expression of ER with AR has been shown to decrease AR transactivation [42]. High concentrations of 5α-DHT stimulate the proliferation of cells of the estrogen-responsive human breast-cancer cell lines MCF-7 and EFM-19 [38]. Androgen-induced proliferation also has been demonstrated in the AR-positive, ER/PR-negative MDA-MB-453 breast-cancer cells [39]. Studies using MDA-MB-453 cells have demonstrated that both estrogens and anti-estrogens have no effect on cell proliferation or viability. AR signaling is intact in MDA-MB-453, and cell growth and survival are responsive to androgen in an AR-dependent and ER-independent manner [26]. It is well known that ER is related to the development of normal breast tissue and the progression of breast cancer, ER expression is associated with increased proliferation of breast-cancer cells, but the cancers are of relatively low malignancy and good prognosis. The expression of AR is likewise associated with increased cell proliferation, with cancers of relatively low malignancy and good prognosis.
4 30 Yoshinari Ogawa & Katsumi Ikeda AR-targeted therapy in TNBC Adjuvant therapy for breast cancer can be generally cytotoxic or specifically biomolecule-targeted. General cytotoxic agents have a DNAdamaging effect on most dividing cells and often induce adverse effects [10]. Targeted therapies interfere with the action of specific biomolecules that are typically overexpressed in the cancer cells [43]. There are only a few targeted-treatment options for TNBC; those of recent clinical interest include poly-(adp-ribose) polymerase (PARP) inhibitors and epidermal growth factor receptor (EGFR) inhibitors. TNBCs do not constitute a homogeneous group (Table 1). AR is expressed in 25 45% of them [12,22-24], and the use of AR-targeted therapies for such cancers is being investigated (Table 2). Most efforts to modulate AR activity have focused on inhibiting the synthesis of androgens or on the identification of androgens that bind to the receptor. A more recent approach is screening for small molecules that inhibit other sites in the steroid-receptor pathways [49]. Furthermore, membrane androgen receptors (mars), which have biological actions different from intracellular AR, have been identified in prostate and breast-cancer cells [50]. Table 1. Rates of AR expression, BRCA1 mutation and EGFR expression in triplenegative breast cancer. Association Prevalence rate AR positive in TNBC 25% to 45%* 1 BRCA1 mutation in TNBC 10%* 2 EGFR expression in TNBC 42% to 71%* 3 TNBC: triple-negative breast cancer. * 1, Ref [12,22-24]; * 2, Ref [44,45]; * 3, Ref [46-48]. Table 2. AR-related targeting therapies in triple-negative breast cancer. Category Target Agent Status Androgen synthesis 5α-red (Inhibitor) Preclinical 17β-HSD5 Agonist hormone AR Bicalutamid Phase II Co-regulation factor ARA70β (Inhibitor) Preclinical New receptor membrane AR Albumin-conjugated testosterone Others Medroxyprogesterone acetate Preclinical Phase II
5 AR in TNBC 31 AR has two endogenous ligands, testosterone and DHT hydroxysteroid dehydrogenase type 5 (17β-HSD5) converts circulating androstenedione to testosterone. In breast tissue, testosterone is converted by 5α-reductase (5 -red) to DHT, and by aromatase to estradiol [51]. 5 -red activity is 4 to 8 times as high in breast-cancer cells as in normal cells [52]. The concentration of circulating DHT is very low both in healthy women and in breast-cancer patients [53], but DHT concentration in breast-cancer tissue is three times as high as that of plasma [54]. Treatment with an aromatase inhibitor increases intratumoral testosterone concentration [55], and aromatase expression is inversely associated with intratumoral DHT levels in breast cancer [56]. These results suggest that high intratumoral concentrations of androgen-converting enzymes play a key role in the effects of androgens on cancer progression. Tissue-specific distribution of these enzymes in women may be suitable for targeted therapy. The usefulness of treatment with aromatase inhibitors in postmenopausal ER-positive breast cancer patients has been established [1]. Inhibition of locally over-expressed 17 -HSD5 and 5 -red may provide treatment options for patients with AR-positive and ERnegative breast cancers. While inhibitors are still at an early stage of development, preclinical studies suggest their potential in the future [57]. Since oral non-steroidal anti-androgens developed in the 1970s, including bicalutamide, flutamide, and nilutamide, are effective in the treatment of prostate cancer, a phase II study is currently being performed to evaluate the efficacy of AR blockade with bicalutamide in AR-positive and ER/PR-negative metastatic breast cancer patients (NCT ). Bicalutamide (Casodex, AstraZeneca) is a widely available, orally active, non-steroidal anti-androgen that competitively inhibits the action of androgens by binding to cytosolic ARs in the target tissue. These antiandrogens have high specificity for the AR, but lack tissue selectivity [51]. An ideal selective androgen receptor modulator (SARM) should have high AR specificity and tissue-selective pharmacological actions [58]. In recent years, SARMs with greater tissue selectivity have been developed to minimize adverse effects [51]; they are currently being investigated mostly for use in prostatic cancer at different stages, but might well contribute to new treatments for AR-positive TNBC. High-dose medroxyprogesterone acetate (MPA) has an anti-proliferative effect in ER-positive and/or PR-positive breast cancer. Before the advent of luteinizing-hormone agonists and third-generation aromatase inhibitors, MPA was a major therapeutic agent in breast cancer, with efficacy comparable to that of tamoxifen [59] and effective for the treatment of endocrine-resistant breast cancer [60]. It is still used occasionally for the treatment of metastatic
6 32 Yoshinari Ogawa & Katsumi Ikeda breast cancer, as a third- or fourth-line endocrine therapy. Clinical studies have revealed that expression of AR, but not ER or PR, predicts response to MPA in breast cancer [61, 62]. It will be necessary to reevaluate the use of MPA for AR-positive TNBC treatment. 5α-red metabolizes progesterone to 5α-dihydroprogesterone, suggesting that this enzyme is also involved in the local regulation of progesterone action [63]. Steroid receptor co-regulators are important in regulating the function of receptors in endocrine organ development and in cancer progression. Unbound AR is bound to chaperone proteins in the cytosol. Once bound by an androgen ligand, AR dissociates from the chaperone proteins and forms a homodimer with the ligand that is translocated to the nucleus and induces a cascade of molecular events, resulting in the activation of target gene transcription [64]. More than 350 nuclear receptor co-regulators have been described [49]. Of these, the AR co-activators ARA70α and ARA70β have distinct effects in mammary gland development and in the progression of breast cancer: ARA70α inhibits and ARA70β promotes proliferation in MCF7 breast-cancer cells; decreased ARA70α expression is associated with an increased tendency towards breast-cancer metastasis; ARA70β has been shown to enhance the invasive ability of MCF7 breast cancer cells [65]. These preclinical studies suggest the potential of AR co-activators for targeted therapy. In recent years, mars, specific G-protein-coupled receptors that mediate a rapid response in the form of non-genomic steroid action [66], have been identified in prostate- and breast-cancer cells [66-68]. mar-dependent biological actions are different from the actions of intracellular ARs: activation of mars with testosterone, in the presence of the antiandrogen flutamide, induces inhibition of cell motility and controlled apoptosis in prostate- and breast- cancer cells [66,68], and potentiates paclitaxel action in hormone-sensitive cells [69]; the mar-induced apoptosis is independent of intracellular AR status. Ligands to mar include natural androgens, albuminconjugated androgens, and flavonol compounds [70-72]. Although free testosterone favors the growth of AR-positive cancer, albumin-conjugated testosterone probably initiates only mar-dependent effects in cells [50]. Development of a specific human-serum-albumin-conjugated androgen for possible treatment of prostate cancer is under investigation [50], and marspecific compounds may have therapeutic potential in breast cancer. Conclusions Targeted endocrine therapy is an important treatment strategy for ERpositive and/or PR-positive breast cancer, but it rarely affects TNBC. AR has
7 AR in TNBC 33 recently received attention in breast-cancer treatment; the data reviewed suggest that it has relevance to breast-cancer biology and may be an important therapeutic target in AR-positive TNBC, especially TNBC that exhibits less AR-ER interaction. We believe that the development of ARtargeted therapy may improve the outcome in patients with TNBC. References 1. Goldhirsch, A. et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer , Ann. Oncol., 22, Hammond, M.E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. 2010, J. Clin. Oncol., 28, Wolff, A.C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. 2007, J. Clin. Oncol., 25, Perou, C.M. et al. Molecular portraits of human breast tumours. 2000, Nature, 406, Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. 2001, Proc. Natl. Acad. Sci. USA, 98, Moriya, T. et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions. 2006, Med. Mol. Morphol., 39, Linn, S.C., and Van t Veer, L.J. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. 2009, Eur. J. Cancer, 45(suppl 1), Cheang, M.C. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. 2009, J. Natl. Cancer Inst., 101, Gucalp, A., and Traina, T.A. Triple-negative breast cancer: role of the androgen receptor. 2010, Cancer J., 16, de Ruijter, T.C. et al. Characteristics of triple-negative breast cancer. 2011, J. Cancer Res. Clin. Oncol., 137, Chacón, R.D., and Costanzo, V. Triple-negative breast cancer. 2010, Breast Cancer Res., 12(suppl 2), Ogawa, Y. et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. 2008, Int. J. Clin. Oncol., 13, Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. 2005, Clin. Cancer. Res., 11, Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. 2007, Clin. Cancer Res., 13, Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. 2008, J. Clin. Oncol., 26, 1275.
8 34 Yoshinari Ogawa & Katsumi Ikeda 16. Kaplan, H.G., and Malmgren, J.A. Impact of triple negative phenotype on breast cancer prognosis. 2008, Breast J., 14, Pienkowski, T., and Zielinski, C.C. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. 2010, Ann. Oncol., 21, Santana-Davila, R., and Perez, E.A. Treatment options for patients with triplenegative breast cancer. 2010, J. Hematol. Oncol., 3, Hall, R.E. et al. Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. 1996, Br. J. Cancer, 74, Kuenen-Boumeester, V. et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. 1996, Eur. J. Cancer, 32A, Gonzalez-Angulo, A.M. et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. 2009, Clin. Cancer. Res., 15, He, J. et al. Prognostic value of androgen receptor expression in operable triplenegative breast cancer: a retrospective analysis based on a tissue microarray.2011, Med. Oncol., Epub ahead of print. 23. Yu, Q. et al Expression of androgen receptor in breast cancer and its significance as a prognostic factor. 2011, Ann. Oncol., 22, Park, S. et al. Expression of androgen receptors in primary breast cancer Ann. Oncol., 21, Rakha, E.A. et al. Prognostic markers in triple-negative breast cancer. 2007, Cancer (Phila.), 109, Peters, A.A. et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. 2009, Cancer Res., 69, Soreide, J.A. et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. 1992, Eur. J. Surg. Oncol., 18, Bryan, R.M. et al. Androgen receptors in breast cancer. 1984, Cancer, 54, Persijn, J.P., Korsten, C.B., and Engelsman, E. Oestrogen and androgen receptors in breast cancer and response to endocrine therapy. 1975, Br. Med. J., 4, Shufelt, C.L., and Braunstein, G.D. Testosterone and the breast. 2008, Menopause Int., 14, Tamimi, R.M. et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. 2006, Arch. Intern. Med., 166, Hankinson, S.E. et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. 1998, J. Natl. Cancer Inst., 90, Kaaks, R. et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). 2005, J. Natl. Cancer Inst., 97, Micheli, A. et al. Plasma testosterone and prognosis of postmenopausal breast cancer patients. 2007, J. Clin. Oncol., 25, Poulin, R., Baker, D., and Labrie, F. Androgen and glucocorticoid receptormediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. 1989, Breast Cancer Res. Treat., 12, 213.
9 AR in TNBC de Launoit, Y. et al. Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11- [16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. 1991, Cancer Res., 51, Wong, Y.C., and Xie, B. The role of androgens in mammary carcinogenesis. 2001, Ital. J. Anat. Embryol., 106, Hackenberg, R., and Schultz, K.D. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids. 1996, J. Steroid Biochem. Mol. Biol., 56, Birrell, S.N., Hall, R.E., and Tilley, W.D. Role of the androgen receptor in human breast cancer. 1998, J. Mammary Gland Biol. Neoplasia, 3, Birrell, S.N. et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. 1995, J. Steroid Biochem. Mol. Biol., 52, Zhang, J. et al. Synergistic effects of androgen and estrogen on the mouse uterus and mammary gland. 2004, Oncol. Rep., 12, Panet-Raymond, V. et al. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. 2000, Mol. Cell. Endocrinol, 167, Tan, A.R., and Swain, S.M. Therapeutic strategies for triple-negative breast cancer. 2008, Cancer J., 14, Foulkes, W.D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. 2003, J. Natl. Cancer Inst., 95, Lakhani, S.R. et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. 2005, Clin. Cancer Res., 11, Rakha, E.A. et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. 2009, Clin. Cancer Res., 15, Meche, A. Cimpean, A.M., and Raica, M. Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer. 2009, Rom. J. Morphol. Embryol., 50, Nalwoga, H. et al. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. 2008, APMIS, 116, Shapiro, D.J., Mao, C., and Cherian, M.T. Small molecule inhibitors as probes for estrogen and androgen receptor action. 2011, J. Biol. Chem., 286, Papadopoulou, N. et al. Membrane androgen receptor activation in prostate and breast tumor cells: molecular signaling and clinical impact. 2009, IUBMB Life, 61, Clarke, B.L., and Khosla, S. New selective estrogen and androgen receptor modulators. 2009, Curr. Opin. Rheumatol., 21, Wiebe, J.P. et al. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. 2000, Cancer Res., 60, Labrie, F. et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. 2003, Endocr. Rev., 24, 152.
10 36 Yoshinari Ogawa & Katsumi Ikeda 54. Recchione, C. et al. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. 1995, J. Steroid Biochem. Mol. Biol., 52, Spinola, P.G. et al. Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors. 1988, Breast Cancer Res. Treat., 12, Suzuki, T. et al. 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. 2007, Int. J. Cancer, 120, Foster, P.A. Steroid metabolism in breast cancer. 2008, Minerva Endocrinol., 33, Negro-Vilar, A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. 1999, J Clin Endocrinol Metab 1999, 84: Muss, H.B. et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. 1988, J. Clin. Oncol., 6, Byrne, M.J. et al. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. 1997, J. Clin. Oncol., 15, Birrell, S.N. et al. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. 1995, J. Clin. Oncol., 13, Buchanan, G. et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. 2005, Cancer Res., 65, Suzuki, T. et al. Androgens in human breast carcinoma. 2010, Med. Mol. Morphol, 43, Kumar, R., Johnson, B.H., and Thompson, E.B. Overview of the structural basis for transcription regulation by nuclear hormone receptors. 2004, Essays Biochem., 40, Wu, X. et al. Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer. 2011, Breast Cancer Res. Treat., 128, Kampa, M. et al. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. 2005, Exp. Cell. Res., 307, Kallergi, G. et al. Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. 2007, Cell. Physiol. Biochem., 20, Hatzoglou, A. et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. 2005, J. Clin. Endocrinol. Metab., 90, Kampa, M. et al. Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells. 2006, Mol. Cancer. Ther., 5, 1342.
11 AR in TNBC Benten, W.P. et al. Functional testosterone receptors in plasma membranes of T cells. 1999, Faseb. J., 13, Gatson, J.P., and Singh, M. Dihydrotestosterone differentially modulates the mitogen-activated protein kinase and the phosphoinositide 3-kinase/Akt pathways through the nuclear and novel membrane androgen receptor in C6 cells. 2006, Endocrinology, 147, Nifli, A.P. et al. Monomeric and oligomeric flavanols are agonists of membrane androgen receptors. 2005, Exp. Cell. Res., 309, 329.
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationMiddle East Journal of Cancer; July 2015; 6(3):
Original Article Middle East Journal of Cancer; July 2015; 6(3): 143-150 A Survey of the Relationship between Serum Testosterone Level and Expressions of Androgen, Progesterone and Estrogen Receptors and
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationEGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
ONCOLOGY REPORTS 21: 413-417, 2009 413 EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer HIROKO NOGI 1, TADASHI KOBAYASHI 2, MASAFUMI SUZUKI 3, ISAO TABEI
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationSPRMs, androgens and breast cancer
SPRMs, androgens and breast cancer Dr Joëlle Desreux BMS 04/06/2016 WHI : the nuclear explosion Looking for the perfect menopause treatment Hot flushes relieve Osteoporosis prevention Cardio-vascular health
More informationPoly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer
Showa Univ J Med Sci 25 2, 83 91, June 2013 Original Poly ADP-ribose Polymerase PARP Staining for Immunohistological Investigation of Primary Breast Cancer Genki TSUKUDA 1 2, Yuko DATE 1, Kunio ASONUMA
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationCrosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea
Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia
More informationClinico- Pathological Features And Out Come Of Triple Negative Breast Cancer
Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationAndrogen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations
Anatomic Pathology / ANDROGEN RECEPTOR IN BREAST CANCER Androgen Receptor Expression in Estrogen Receptor Negative Breast Cancer Immunohistochemical, Clinical, and Prognostic Associations S. Nicholas Agoff,
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationA Case of Androgen Receptor-positive Triple Negative Breast Cancer with Good Response to Anti-androgen Therapy
Showa Univ J Med Sci 27 2, 131 136, June 2015 Case Report A Case of Androgen Receptor-positive Triple Negative Breast Cancer with Good Response to Anti-androgen Therapy Megumi NAKAJIMA 1 2, Sadako AKASHI-TANAKA
More informationLoss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer
352 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer Aye Aye Thike 1,2,3,4, Luke
More informationHeather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationA Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer
Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationSerum levels of 25-OH vitamin D, folic acid and testosterone in patients with breast cancer: a case control study
Asian Biomedicine Vol. 5 No. 5 October 2011; 663-667 Brief communication (Original) DOI: 10.5372/1905-7415.0505.097 Serum levels of 25-OH vitamin D, folic acid and testosterone in patients with breast
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationCLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS
CLINICOPATHOLOGIC FEATURES AND MOLECULAR SUBTYPES OF BREAST CANCER IN FEZ-MEKNES REGION (MOROCCO): A STUDY OF 390 PATIENTS S. Chahbouni¹, A. Amarti 2, N. Hammas 3, L. Chbani 3, H. El fatemi 3 1 Department
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationBreast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
DOI 10.1007/s00268-015-3133-2 ORIGINAL SCIENTIFIC REPORT Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationTriple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany
Triple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany Triple-Negative Breast Cancer (TNBC) 2018 Presentation Outline The molecular heterogeneity
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationExpression of androgen receptors in primary breast cancer
Annals of Oncology 21: 488 492, 2010 doi:10.1093/annonc/mdp510 Published online 3 November 2009 Expression of androgen receptors in primary breast cancer S. Park 1, J. Koo 2, H. S. Park 1, J.-H. Kim 1,
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationCorrelation Between GATA-3, Ki67 and p53 Expressions to Histopathology Grading of Breast Cancer in Makassar, Indonesia
Cancer Research Journal 2016; 4(3): 43-47 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20160403.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Correlation Between GATA-3, Ki67
More informationNitin Telang1, Guo Li2, Meena Katdare3,4 Daniel w. Sepkovic5,
Preventive Efficacy of the Chinese Nutritional Herb Epimedium grandiflorum in a Preclinical Cell Culture Model for Luminal A Molecular Subtype of Breast Cancer Nitin Telang1, Guo Li2, Meena Katdare3,4
More informationExpression of androgen receptor in breast cancer and its significance as a prognostic factor
Annals of Oncology 22: 1288 1294, 2011 doi:10.1093/annonc/mdq586 Published online 25 November 2010 Expression of androgen receptor in breast cancer and its significance as a prognostic factor Q. Yu 1,2,Y.Niu
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationONCOLOGY LETTERS 7: , 2014
866 Investigating the discernible and distinct effects of platinum based chemotherapy regimens for metastatic triple negative breast cancer on time to progression DANIEL KHALAF 1,2, JOHN F. HILTON 2, MARK
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationCHARLES M. PEROU. The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
The Oncologist Molecular Stratification of Triple-Negative Breast Cancers CHARLES M. PEROU The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Key Words. Triple-negative breast
More informationHealth Disparities Advances in Breast Cancer Treatment. Jo Anne Zujewski April 27, 2009
Health Disparities Advances in Breast Cancer Treatment Jo Anne Zujewski April 27, 2009 Disclaimer Breast Cancer Incidence 1994-2003 Breast Cancer Mortality 1994-2003 Access to Care Comorbidity Biology
More informationClinical Oncology - Science in focus - Editorial. Understanding oestrogen receptor function in breast cancer, and its interaction with the
Clinical Oncology - Science in focus - Editorial TITLE: Understanding oestrogen receptor function in breast cancer, and its interaction with the progesterone receptor. New preclinical findings and their
More informationPresent Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy
Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is
More informationAndrogens and prostate cancer: insights from abiraterone acetate and other novel agents
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian
More informationLecture 10: Hormonal agents
Lecture 10: Hormonal agents The survival and proliferation (growth) of some cancer cells is dependent on the action of steroid hormones. Early stage breast cancer and early stage prostate cancer are the
More informationMolecular classification of breast cancer implications for pathologists. Sarah E Pinder
Molecular classification of breast cancer implications for pathologists Sarah E Pinder Courtesy of CW Elston Histological types Breast Cancer Special Types 17 morphological special types 25-30% of all
More informationRESEARCH ARTICLE. Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India
APJCP.2016.17.6.2995 RESEARCH ARTICLE Eight Year Survival Analysis of Patients with Triple Negative Breast Cancer in India Dinesh Chandra Doval 1,2 *, P Suresh 1, Rupal Sinha 2, Saud Azam 2, Ullas Batra
More informationResponse to Paclitaxel in Node-positive Triple Negative Breast Cancer
J Korean Surg Soc 2010;79:173-179 DOI: 10.4174/jkss.2010.79.3.173 원 저 Response to Paclitaxel in Node-positive Triple Negative Breast Cancer Department of Surgery, Kosin University College of Medicine,
More informationEditorial Process: Submission:11/30/2017 Acceptance:01/04/2019
RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative
More informationModern classification of breast cancer-should we stick with morphology or convert to molecular profiles?
Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Ian Ellis Professor of Cancer Pathology Molecular Medical Sciences University of Nottingham Dept
More informationLow ER+ Breast Cancer. Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD ABSTRACT
Low ER+ Breast Cancer Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD From the Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationTherapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition Lisa A Carey, MD Disclosures for Lisa A Carey, MD No real or apparent conflicts of interest to disclose Basal-Like
More informationUpdates in Molecular Classification of Breast Cancer. Emmanuel Agosto-Arroyo, MD Assistant Member Department of Anatomic Pathology
Updates in Molecular Classification of Breast Cancer Emmanuel Agosto-Arroyo, MD Assistant Member Department of Anatomic Pathology 3/3/2018 Disclosure There are no conflicts of interest. Objectives Describe
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationThe Expression of Basal Cytokeratins in Breast Cancers
Global Journal of Medical Research: C Microbiology and Pathology Volume 17 Issue 2 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationBreast cancer is the most common malignancy among
A Targetable Androgen Receptor Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers Damoun Safarpour, MD; Fattaneh A. Tavassoli, MD Context. Triple-negative breast cancer (TNBC) is a
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationClinical pathological and epidemiological study of triple negative breast cancer
International Journal of Research in Medical Sciences Ajay A et al. Int J Res Med Sci. 217 Jun;5(6):2657-2661 www.msjonline.org pissn 232-71 eissn 232-12 Original Research Article DOI: http://dx.doi.org/1.1823/232-12.ijrms2172465
More informationDiabetes Mellitus and Breast Cancer
Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationBreast cancer presents a major risk to American. Cancer recurrence and survival in patients with early-stage triple-negative breast cancer
Original Research Cancer recurrence and survival in patients with early-stage triple-negative breast cancer Neal P. Christiansen, MD, 1 Lei Chen, MD, PhD, 2 James Gilmore, DPharm, 3 and Stephen Szabo,
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/103187/ This is the author s version of a work that was submitted to / accepted
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationHormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index
Hormonal Health PATIENT: Sample Report TEST REF: TST-12345 Hormonal Health 0.61 0.30-1.13 ng/ml DHEA-S 91 35-430 mcg/dl tient: SAMPLE TIENT e: x: N: Sex Binding Globulin 80 18-114 nmol/l Testosterone 0.34
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationBreast Cancer. Key Words. Breast cancer Estrogen Estrone sulfate Steroid sulfatase Sulfatase inhibitor
The Oncologist Breast Cancer Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer SUSANNAH J. STANWAY, a PATRICK DELAVAULT, b ATUL PUROHIT, a L. W. LAWRENCE WOO, c CHRISTOPHE THURIEAU,
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationEstrogen (ER) receptor biology: Implications for HRT? Dr. Christoph A. Meier Endocrine Unit University Hospital Geneva
Estrogen (ER) receptor biology: Implications for HRT? Dr. Christoph A. Meier Endocrine Unit University Hospital Geneva Estrogens prevent postmenopausal bone-loss HRT & osteoporosis bip & estrogen bip
More informationFinding the Positives in Triple-Negative Breast Cancer:
Finding the Positives in Triple-Negative Breast Cancer: A Three-Part Live CME Webcast Series Seminar I Wednesday, March 3, 2010 Faculty Clifford Hudis, MD Lisa A Carey, MD Seminar II Thursday, March 11,
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationOverview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 2010
Original Article Overview of breast cancerpatients and their prognostic factors treated in Baghdad teaching hospital/ oncology department in the year 21 * DMRT clinical oncology, MSc. pathology. Summary:
More information